Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms
S. H. Rosenthal, A. Gerasimova, C. Ma, H.-R. Li, A. Grupe, H. Chong, A. Acab, A. Smolgovsky, R. Owen, C. Elzinga, R. Chen, D. Sugganth, T. Freitas, J. Graham, K. Champion, , F. Lacbawan
The paper validates a 48-gene NGS panel for detecting actionable genomic mutations in myeloid neoplasms, showing high sensitivity and specificity.
bioRxiv · Nov 30, 2020Cancer Biology